Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.

Farrokh DehdashtiNingying WuRon BoseMichael J NaughtonCynthia X MaBernadette V Marquez-NostraPhilipp DiebolderCedric MpoyBuck E RogersSuzanne E LapiRichard LaforestBarry A Siegel

Published in: Breast cancer research and treatment (2018)

[89Zr]trastuzumab has the potential to characterize the HER2 status of the complete tumor burden in patients with breast cancer, thus obviating repeat or multiple tissue sampling to assess intrapatient heterogeneity of HER2 status.

Keyphrases

pet ct
epidermal growth factor receptor
pet imaging
positron emission tomography
metastatic breast cancer
single cell
risk factors
magnetic resonance imaging
tyrosine kinase
young adults
human health